Getinge and Neobiomics received Swecare's export awards

Two companies received awards during Swecare's annual conference.

Stockholm and Uppsala jointly form a life science cluster

Stockholm and Uppsala are strengthening cooperation in medical research and biotech.

In-Depth Insights into the Most Useful ZEISS Metrology Expert Tips

Free webinar June 24th, 2025, 9:00-9:45 AM and 5:00-5:45 PM.

After the threat of tariffs – Novartis invests 230 billion in the USA

Pharmaceutical giant Novartis plans to invest 23 billion dollarsover the next five years to expand its production in the USA. The goal is for all medicines dest...

Smartzoom 100 – The New Digital Microscope for Maximum Efficiency

Free webinar July 1, 9:00-9:45 AM CEST and 5:00-5:45 PM CEST.

Ukraine war fuels rise of totally resistent bacteria

War-torn Ukraine is not just suffering from hostile attacks from a foreign aggressor, but also from the threat of a totally resistant and contagious bacteria.

FDA plans to replace animal testing with AI – “Paradigm shift”

The requirement for animal testing in drug development will be phased out and replaced by AI, according to an announcement by the FDA. The decision has been met...

Lonza

Pressen att publicera göder rovtidskrifterna

Forskare som lockas, eller luras, att publicera sig i tvivelaktiga vetenskapliga tidskrifter är ett fenomen som vuxit. Men vad är egentligen en rovtidskrift, oc...

Tau-targeted Alzheimer's drug gets Fast Track designation in the USA

Biogen's Alzheimer's candidate BIIB080 has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA).

Biovica får patent för att förutse immunterapi-effekt

Diagnostikbolaget Biovica har fått ett europeiskt patent beviljat för att förutsäga behandlingseffekt av immunterapier vid cancer med hjälp av företagets produkt Divitum TKa.

New drug to simplify treatment of hemophilia

A new type of treatment for hemophilia, which only needs to be administered every two months, has been approved by the U.S. Food and Drug Administration (FDA).

Her company is developing a new tablet form obesity drug

Obesity and diabetes are the primary targets of a new tablet treatment under development by Malmö-based Pila Pharma. The company’s ambition is to take on the bi...

Index rekommenderas avsluta studie: ”Överraskande och nedslående”

En oberoende kommitté rekommenderar Index Pharmaceuticals att avbryta sin fas III-studie med läkemedelskandidaten Cobitolimod, som prövas som behandling mot ulc...

Eli Lilly requests re-examination of Alzheimer's drug recommendation

Eli Lilly has requested that the EMA re-examine its opinion on the company's Alzheimer's drug, Kisunla, the agency announced on Friday.

ZEISS unveils AI-powered Research Data Platform

Collaboration with Boehringer Ingelheim champions the future of personalized eye care.

An organ seldom in the spotlight – but utterly vital

The kidneys consist of more than 40 types of cells and have more functions in the body than most people know. Julie Williams leads AstraZeneca’s work in preclin...

Revealing the secrets of a part

CT inspection in automation technology at Festo.

MSD i storaffär – köper rättigheter till hjärt-kärlkandidat

Merck & Co, känt som MSD utanför USA och Kanada, har ingått ett exklusivt licensavtal med kinesiska Hengrui Pharma. Avtalet rör rättigheterna till läkemedelskan...

ZEISS continues to drive digital era forward in ophthalmology

2 million digitally planned cataract cases in the U.S. alone.

Several departures at the top at Nykode

Members of both the management and the board are leaving the Norwegian biotech company Nykode.

Snabbtest ska hitta rätt behandling mot giftormens bett

Var sjätte sekund råkar någon på vår jord ut för ett ormbett, och varje gång startar en jakt mot klockan. Vad var det för orm som bet, och vilket motgift kan hj...

Korbinian Löbmann leads scientific meeting on drug formulation: High activity in the field

Korbinian Löbmann has moderated New Updates in Drug Formulation & Bioavailability several times before. Now he is once again taking on the scientific meeting. L...

Aqilion's licensing journey: From Merck partnership to new opportunities

Be extremely meticulous with your scientific data, but spend just as much time and effort on business development. That piece of advice comes from Aqilion's CEO...